RMC-4630 + osimertinib

RMC-4630 + osimertinib is an investigational **combination therapy** under clinical development for the treatment of locally advanced or metastatic EGFR mutant non-small cell lung cancer (NSCLC) not amenable to curative surgery or radiotherapy. **RMC-4630 (vociprotafib)** is an orally bioavailable, selective, allosteric inhibitor of protein tyrosine phosphatase non-receptor type 11 (SHP2), which is a key regulator of RAS/MAPK signaling. **Osimertinib** is a third-generation, irreversible EGFR tyrosine kinase inhibitor targeting activating and resistance mutations including T790M. The combination is studied primarily in patients who have progressed on previous osimertinib monotherapy or regimen, aiming to overcome resistance and provide improved antitumor activity by dual blockade of EGFR and SHP2 pathways[4][5][3].

Other names

Vociprotafib + osimertinib